Showing results (111-120 of 375) with videos related to
Sort By:
Pageof 38
Journal of Nuclear Medicine Technology|February 6, 2016
177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal FunctionRohit Ranade, Sandip BasuJournal of Cancer Research and Therapeutics|February 17, 2016
Focal thyroid incidentaloma on whole body fluorodeoxyglucose positron emission tomography/computed tomography in known cancer patients: A case-based discussion with a series of three examplesMangala Targe, Sandip BasuJournal of Nuclear Medicine Technology|March 1, 2020
Comparison of Dual-Tracer PET and CT Features to Conventional Risk Categories in Assessing Response to <sup>177</sup>Lu-PSMA-617 Therapy for Metastatic Prostate Adenocarcinoma with Urinary Bladder InvolvementAadil Adnan, Sandip BasuPET Clinics|March 9, 2020
PET/Computed Tomography in Pulmonary and Thoracic Inflammatory Diseases (Including Cardiac Sarcoidosis): The Current Role and Future PromisesAshwini Kalshetty, Sandip BasuWorld Journal of Nuclear Medicine|February 24, 2021
Interpreting discordance on dual-tracer positron emission tomography-computed tomography in the setting of metastatic neuroendocrine tumor: Detection of metachronous triple-negative breast carcinomaAshwini Kalshetty, Sandip BasuPET Clinics|September 24, 2022
Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer: A Futuristic PerspectiveAadil Adnan, Sandip BasuIndian Journal of Nuclear Medicine : IJNM : the Official Journal of the Society of Nuclear Medicine, India|July 3, 2018
Thyroglobulin "Nonsecretor" Metastatic Poorly Differentiated Thyroid Carcinoma with Noniodine Concentrating Disease and Aggressive Clinical Course: A Clinical Case SeriesAshwini Kalshetty, Sandip BasuJournal of Nuclear Medicine Technology|August 25, 2018
Small Cell Transformation of Metastatic Prostate Adenocarcinoma Diagnosed by Dual-Tracer PET/CT (<sup>68</sup>Ga-PSMA and <sup>18</sup>F-FDG): Potential Clinical Utility in Therapeutic Decision Making and Treatment MonitoringRahul Parghane, Sandip BasuJournal of Nuclear Medicine Technology|October 17, 2015
Favorable Response of Metastatic Merkel Cell Carcinoma to Targeted 177Lu-DOTATATE Therapy: Will PRRT Evolve to Become an Important Approach in Receptor-Positive Cases?Sandip Basu, Rohit RanadeWorld Journal of Nuclear Medicine|February 6, 2018
<sup>177</sup>Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Borderline Low and Discordant Renal Parameters: Treatment Feasibility Assessment by Sequential Estimation of Triple Parameters and Filtration FractionChinna Naik, Sandip BasuPageof 38